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Abstract
Background: Transmissible spongiform encephalopathies (TSEs), a group of neurodegenerative
diseases, are thought to be caused by an abnormal isoform of a naturally occurring protein known
as cellular prion protein, PrPC. The abnormal form of prion protein, PrPSc accumulates in the brain
of affected individuals. Both isoforms are encoded by the same prion protein gene (PRNP), and the
structural changes occur post-translationally. Certain mutations in the PRNP gene result in genetic
TSEs or increased susceptibility to TSEs.
Case presentation: A 70 year old woman was admitted to the hospital with severe confusion
and inability to walk. Relatives recognized memory loss, gait and behavioral disturbances over a six
month period prior to hospitalization. Neurological examination revealed Creutzfeldt-Jakob
disease (CJD) related symptoms such as incontinence, Babinski sign and myoclonus. EEG showed
periodic sharp waves typical of sporadic CJD and cerebrospinal fluid analysis (CSF) was positive for
the presence of the 14-3-3-protein. As the disease progressed the patient developed akinetic
mutism and died in the tenth month after onset of the disease symptoms. Unfortunately, no
autopsy material was available. PRNP sequencing showed the occurrence of a point mutation on
one allele at codon 193, which is altered from ACC, coding for a threonine, to ATC, encoding an
isoleucine (T193I).
Conclusion: Here we report a novel mutation of the PRNP gene found in an elderly female patient
resulting in heterozygosity for isoleucine and threonine at codon 193, in which normally
homozygosity for threonine is expected (T193). The patient presented typical clinical symptoms of
CJD. EEG findings and the presence of the 14-3-3 protein in the CSF, contributed to CJD diagnosis,
allowing the classification of this case as a probable CJD according to the World Health
Organization (WHO) accepted criteria.
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Background
Transmissible spongiform encephalopathies (TSEs) are a
group of neurodegenerative diseases of the central nerv-
ous system. These diseases share common features and
can be found in both humans and animals. The infectious
agent of TSEs is believed to be an abnormal isoform of a
naturally occurring protein known as cellular prion pro-
tein, PrPC [1]. The abnormal prion protein isoform (PrPSc)
accumulates in the brains of affected individuals. Both
isoforms are encoded by the same gene PRNP, and the
structural changes occur post-translationally. The lack of
the endogenous PrP protein prevents the development of
TSEs, as has been demonstrated in transgenic mice lacking
the PRNP gene [2]. On the other hand, mutations that
exist in the PRNP gene might facilitate the development of
TSEs [3-5]. The most common TSE in humans is Creut-
zfeldt-Jakob disease (CJD), accounting for 85% of all TSE
cases in humans [6]. There are three types of CJD, sporadic
CJD (sCJD), infectious CJD (iCJD) and genetic CJD
(gCJD). sCJD arises spontaneously, with unknown aetiol-
ogy and affects mainly the elderly population at a fre-
quency of one per million per year. iCJD is caused by the
consumption of prion contaminated food or by medical
treatments with prion contaminated biological materials
and surgical instruments [7]. In gCJD, mutations in the
PRNP  gene predispose to disease [7,8] by causing the
expression of PrP protein with modified primary struc-
ture.
Several mutations have been identified in the prion pro-
tein, encoded by the PRNP gene. More than thirty have
been associated or directly linked to TSEs [9-11]. Here we
report a novel mutation in codon 193 (T193I) of the
PRNP gene, in a patient with clinical features and EEG
findings typical of CJD. Normally, codon 193, comprising
nucleotides ACC, codes for a threonine, whereas in the




The patient was a 70 year old woman, with a history of
diabetes mellitus, who was admitted to the hospital with
confusion and inability to walk. Six months prior to
admission, her relatives had started recognizing neurolog-
ical symptoms, such as gait disturbance, memory loss and
behavioral disturbances (irritability and aggression). Over
the six month period that preceded the admission to the
hospital, a rapid deterioration of her cognitive function
was observed. She also displayed visual hallucinations
and delusions requiring antipsychotic treatment.
On admission, the patient was bedridden, incontinent,
severely confused with generalized hyperreflexia, bilateral
Babinski sign, startle responses elicited by mild external
stimuli, and multifocal generalized myoclonus which
evolved to rhythmic. Two months later she developed aki-
netic mutism. The patient died three months after hospi-
talization.
Routine hematological and biochemical examinations
produced normal results. CSF examination (protein, glu-
cose and cell count) was normal, while EEG showed gen-
eralized findings, periodic triphasic sharp waves, recurring
at intervals of 0.5–1 sec (Fig 1). Magnetic resonance imag-
ing of the brain showed no significant abnormalities,
except for a minor brain atrophy which could be related
to the patient's age.
There was a lack of family history concerning neurological
disorders. Although the clinical course followed the typi-
cal rapid progression of CJD, the relatives did not consent
to having a neuropathological examination carried out,
neither did they agree to further genetic investigation of
the immediate family members, and thus it has not been
possible to determine if the mutation has been passed to
the patient's offspring.
14-3-3 protein detection in the CSF
Cerebrospinal fluid (CSF) was collected by lumbar punc-
ture. Both the lumbar puncture and the EEG, were per-
formed three and eight days after the patient's admission
to the hospital (about six months after the occurrence of
the reported symptoms observed by family members).
Electroencephalogram of the suspected CJD patient showing  typical periodic bursts of triphasic sharp waves Figure 1
Electroencephalogram of the suspected CJD patient 
showing typical periodic bursts of triphasic sharp 
waves.BMC Infectious Diseases 2006, 6:169 http://www.biomedcentral.com/1471-2334/6/169
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The proteins contained in 30 µl of CSF were separated on
a 12% polyacrylamide gel and then transferred onto a pol-
yvinylidene fluoride (PVDF) membrane. The membrane
was stained as described [12] with a polyclonal anti-14-3-
3β antibody (Santa Cruz, sc-629) and an alkaline phos-
phatase conjugated secondary antibody (Pierce, 31340).
CDP-Phototope Star (New England Biolabs, N701) was
used to develop the membrane.
Detection of 14-3-3 protein in CSF, is considered to be a
sensitive and specific marker for sporadic CJD. CSF tested
positive twice for the presence of 14-3-3 protein (Fig. 2),
supporting a probable CJD diagnosis [13,14].
DNA purification and sequencing
Genomic DNA was isolated from whole blood using
Promega's Wizard genomic DNA purification kit accord-
ing to the manufacturer's instructions. The proper quality
and quantity of the genomic DNA for polymerase chain
reaction (PCR) amplification was confirmed by spectro-
photometry. The PRNP open reading frame was amplified
by PCR with the following primers designed as cloning
primers; HumoS: 5'- GCT CTA GAG CAT GGC GAA CCT
T and HumoAS: 5'- GCT CTA GAT CAT CCC ACG ATC
AGG AA. The bases of the primers corresponding to the
open reading frame of PRNP are shown in bold. Amplifi-
cation was confirmed by agarose gel electrophoresis.
Sequencing was performed first at MWG-Biotech (Ebers-
berg, Germany) and then the sequencing results were con-
firmed by two other independent laboratories
(Department of Neurology, University of Crete, MRC
Prion Unit and Department of Neurodegenerative Dis-
eases, University College, London).
PRNP sequence analysis revealed the existence of a causa-
tive mutation at codon 193. Upon comparison with the
762 bp sequence of the human PrP cDNA record
(Genebank accession number M13899), it was found that
the sequenced PRNP gene exhibits a point mutation at
codon 193, comprising nucleotides 577–579. The point
mutation occurs as a C to T transition at position 578
which causes the switch of codon 193 from ACC, encod-
ing threonine, to ATC, encoding isoleucine. As shown on
the electropherogram (Fig. 3), the patient is heterozygous
for threonine and isoleucine at codon 193. The patient
was found to be homozygous for methionine at codon
129 (M129).
Conclusion and discussion
The genotype of the host seems to play an important role
in prion disease pathogenesis. Susceptibility to prion dis-
eases is enhanced if the individual possesses certain geno-
types. The human genetic TSEs account for 5–15% of
human TSE cases and have been linked to specific muta-
tions of the PRNP gene [9,10,15]. Susceptibility to sCJD
has been associated with homozygosity for methionine at
the polymorphic codon 129 [16,17]. In the Greek popu-
lation 50% homozygosity for M129 has been reported
[18].
Here we report the case of a 70 year old female patient car-
rying the T193I mutation, who presented typical clinical
symptoms of CJD. The presence of a mutation in the
PRNP gene along with the presentation of symptoms typ-
ical for CJD supports the diagnosis of probable CJD
according to the WHO accepted criteria [13]. The
observed mutation was associated with homozygosity for
methionine at codon 129. The patient's age at onset of the
symptoms and the homozygosity M129 is consistent with
the average age at onset observed in other gCJD cases [9].
The PrP protein primary structure is well conserved over a
variety of mammals [19]. Interestingly, T193 of the
human PrP protein can be found in the homologue pro-
Immunoblot detection of 14-3-3 in the CSF Figure 2
Immunoblot detection of 14-3-3 in the CSF. The patient was tested positive for the presence of 14-3-3 in the 
CSF. Lane 1: healthy control, lane 2: patient sample, lane 3: positive control (CSF) and lane 4: positive control 
(brain tissue homogenate)BMC Infectious Diseases 2006, 6:169 http://www.biomedcentral.com/1471-2334/6/169
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teins at the same position in all thirty six species listed in
the cited publication, except in shrew, in which it is
replaced by serine. Threonine and serine, are both
hydrophilic polar amino acids with uncharged side
chains, while isoleucine is a hydrophobic amino acid. The
T193I mutation reported here, may affect the three
dimensional structure of the protein. Since TSEs are linked
to conformational changes of the prion protein, this
mutation may be associated with the occurrence of the
disease.
The mutation reported here results in an amino acid
change within α-helix 2 (H2) of the PrP protein, which
comprises amino acids 173–194 [20]. H2 is characterized
by the occurrence of different causative mutations, most
of which are linked to the appearance of a CJD phenotype
[10].
Of particular interest is the T188A mutation, which is the
most closely located mutation to codon 193 on H2 that
has been reported [21]. Similarly to T193I, in the T188A
case, threonine is replaced by a hydrophobic residue and
both cases emerged with homozygosity for methionine at
codon 129. Both patients were women of similar age i.e.
70 and 69 years old, respectively, and the brain MRI scan
revealed no typical CJD findings, but a minor brain atro-
phy. EEG and the CSF analysis for the 14-3-3 protein were
typical for sCJD in both cases. Clinical symptoms like the
failure of cognitive abilities, myoclonus and visual distur-
bances were observed in both patients. Additionally, both
patients share the absence of family history for dementia,
which is probably caused by the reduced penetrance of the
mutation [9,22].
Codon 196 is very closely located to codon 193 although
it does not belong to H2. The E196K mutation associated
with M129 homozygosity [22] affected a 69 year old
woman, who in contrast to the patient reported here, had
a family history of dementia. The onset symptoms in both
patients included behavioral abnormalities, albeit of a dif-
ferent type (the patient carrying the E196K mutation dis-
played emotional lability, inappropriate giggling,
anorexia versus irritability and aggression). Gait distur-
bances were observed in both patients and both became
bedridden as the disease progressed. Furthermore, both
patients tested positive for the presence of 14-3-3 protein
in the CSF. However, the EEG of the patient carrying the
E196K mutation showed no periodic activity and there
was a slight difference in the period from the onset of
symptoms to death (10 versus 12 months).
During the CJD surveillance program supported by the
Greek Ministry of Health, a total of twenty five patients
suspected of having CJD, and ten of their relatives, were
genotypically examined with respect to the PRNP gene.
Full sequencing of the above samples revealed no abnor-
malities in the PRNP  sequence and in all samples
homozygosity for threonine at codon 193 was found.
These data indicate that the T193I alteration of the PrP
protein reported here is a mutation rather than a rare pol-
ymorphism.
Such mutations may either be inherited by the individual
from the parents following the rules of Mendelian inher-
itance, or they may occur spontaneously. In the second
case, a lack of family history should be expected. Lack of
family history in gCJD cases is often reported [9] and it is
suggested to occur due to the partial penetrance of the
mutation.
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Electropherogram of the DNA sequencing showing the posi- tion 193 were the mutation was detected Figure 3
Electropherogram of the DNA sequencing showing the posi-
tion 193 were the mutation was detected. Codon ACC 
codes for a Threonine and codon ATC for an Isoleucine. The 
arrow indicates the position on the electropherogram, 
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